Horizon Pharma (HZNP) PT Raised to $38 at Piper Jaffray; More Bullish on Pennsaid and Ravicti Upside
Tweet Send to a Friend
Piper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Horizon Pharma (NASDAQ: HZNP) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
